In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
HOME > BUSINESS
BUSINESS
- Febuxostat Approved for Hyperuricemia Associated with Cancer Chemotherapy in Europe: Teijin Pharma
July 1, 2015
- Taisho, Ablynx of Belgium to Collaborate for Development and Commercialization of Anti-TNF-α Nanobody
July 1, 2015
- Otsuka Initiates Voluntary Recall of Uniphyl
June 30, 2015
- Takecab Slips to 2nd Place as Suglat Comes 1st in GP Market in May: Anterio Ranking
June 30, 2015
- Bayer Obtains Approval for Eylea for Macular Edema Secondary to Retinal Vein Occlusion
June 30, 2015
- Study for Myelodysplastic Syndrome in Japan: SymBio
June 30, 2015
- Takeda Chairman Hasegawa Gives Up Representative Rights
June 29, 2015
- Aspen Japan Takes Over Decadron from MSD
June 29, 2015
- UCB Japan Applies for Approval of Antiepileptic Agent Lacosamide in Japan
June 29, 2015
- RaQualia Regains Domestic Rights to Dalbavancin from Allergan
June 29, 2015
- Lixiana Gets EU Regulatory Approval: Daiichi Sankyo
June 26, 2015
- EU OKs Fycompa as Adjunct Therapy for PGTC Seizures: Eisai
June 26, 2015
- Sosei Group “Not in Hurry” to License Out Compounds Obtained through Heptares Acquisition: President Tamura
June 26, 2015
- Naldemedine Meets Primary, Secondary Endpoints in Japanese PIII Study for the Treatment of OIC in Cancer Patients: Shionogi
June 26, 2015
- Novartis Seeks Japan Approval of Ceritinib
June 25, 2015
- Takeda CFO Roger to Resign in under 2 Years
June 25, 2015
- Japan Vaccine Studying Marketing Strategy for 3 Seasonal Flu Vaccines, Marketing System for Adult Vaccines as Well
June 24, 2015
- AnGes MG Grants MTPC Marketing Rights for HGF Gene Treatment for Peripheral Vascular Diseases in Japan
June 24, 2015
- Hemophilia A Treatment Candidate to Move to PIII During 2015 Based on Favorable Results in PI/II Studies: Chugai
June 24, 2015
- Lilly Japan Oncology Chief Hopeful on Cyramza Growth
June 23, 2015
ページ
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…